AXL

Balazs Halmos, Xue wen Liu

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

AXL is a member of the TAM family, a receptor tyrosine kinase (RTK) subfamily composed of AXL, TYRO-3, and MER. Its main ligand is the vitamin K-dependent protein named growth arrest-specific gene 6 (Gas6). AXL is abnormally activated in many cancers by protein overexpression, point mutations, and gene fusions. The Gas6-AXL axis contributes to tumor progression, invasion, metastasis, and resistance both to chemotherapeutic and targeted anticancer therapies in a wide variety of cancers. In this review, we describe the biology of AXL, review diverse mechanisms of activation and the established and putative roles of AXL as a biomarker and therapeutic target in cancer therapy. Pre-clinical and clinical data for anti-AXL therapies to date are also summarized.

Original languageEnglish (US)
Title of host publicationCancer Therapeutic Targets
PublisherSpringer New York
Pages661-671
Number of pages11
Volume2-2
ISBN (Electronic)9781441907172
ISBN (Print)9781441907165
DOIs
StatePublished - Jan 1 2017

Fingerprint

Genes
Neoplasms
Vitamin K
Receptor Protein-Tyrosine Kinases
Biomarkers
Tumors
Gene Fusion
Proteins
Fusion reactions
Therapeutics
Growth
Chemical activation
Point Mutation
Ligands
Neoplasm Metastasis

Keywords

  • Acquired TKI resistance
  • Activated mechanisms
  • AXL
  • Epithelial-mesenchymal transition (EMT)
  • Gas6
  • Overexpression
  • Point mutations
  • Receptor tyrosine kinase (RTK)
  • TAM family
  • Targeted inhibitors

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Halmos, B., & Liu, X. W. (2017). AXL. In Cancer Therapeutic Targets (Vol. 2-2, pp. 661-671). Springer New York. https://doi.org/10.1007/978-1-4419-0717-2_114

AXL. / Halmos, Balazs; Liu, Xue wen.

Cancer Therapeutic Targets. Vol. 2-2 Springer New York, 2017. p. 661-671.

Research output: Chapter in Book/Report/Conference proceedingChapter

Halmos, B & Liu, XW 2017, AXL. in Cancer Therapeutic Targets. vol. 2-2, Springer New York, pp. 661-671. https://doi.org/10.1007/978-1-4419-0717-2_114
Halmos B, Liu XW. AXL. In Cancer Therapeutic Targets. Vol. 2-2. Springer New York. 2017. p. 661-671 https://doi.org/10.1007/978-1-4419-0717-2_114
Halmos, Balazs ; Liu, Xue wen. / AXL. Cancer Therapeutic Targets. Vol. 2-2 Springer New York, 2017. pp. 661-671
@inbook{0e473ddea2b74ac3976d0a6500a76ddd,
title = "AXL",
abstract = "AXL is a member of the TAM family, a receptor tyrosine kinase (RTK) subfamily composed of AXL, TYRO-3, and MER. Its main ligand is the vitamin K-dependent protein named growth arrest-specific gene 6 (Gas6). AXL is abnormally activated in many cancers by protein overexpression, point mutations, and gene fusions. The Gas6-AXL axis contributes to tumor progression, invasion, metastasis, and resistance both to chemotherapeutic and targeted anticancer therapies in a wide variety of cancers. In this review, we describe the biology of AXL, review diverse mechanisms of activation and the established and putative roles of AXL as a biomarker and therapeutic target in cancer therapy. Pre-clinical and clinical data for anti-AXL therapies to date are also summarized.",
keywords = "Acquired TKI resistance, Activated mechanisms, AXL, Epithelial-mesenchymal transition (EMT), Gas6, Overexpression, Point mutations, Receptor tyrosine kinase (RTK), TAM family, Targeted inhibitors",
author = "Balazs Halmos and Liu, {Xue wen}",
year = "2017",
month = "1",
day = "1",
doi = "10.1007/978-1-4419-0717-2_114",
language = "English (US)",
isbn = "9781441907165",
volume = "2-2",
pages = "661--671",
booktitle = "Cancer Therapeutic Targets",
publisher = "Springer New York",

}

TY - CHAP

T1 - AXL

AU - Halmos, Balazs

AU - Liu, Xue wen

PY - 2017/1/1

Y1 - 2017/1/1

N2 - AXL is a member of the TAM family, a receptor tyrosine kinase (RTK) subfamily composed of AXL, TYRO-3, and MER. Its main ligand is the vitamin K-dependent protein named growth arrest-specific gene 6 (Gas6). AXL is abnormally activated in many cancers by protein overexpression, point mutations, and gene fusions. The Gas6-AXL axis contributes to tumor progression, invasion, metastasis, and resistance both to chemotherapeutic and targeted anticancer therapies in a wide variety of cancers. In this review, we describe the biology of AXL, review diverse mechanisms of activation and the established and putative roles of AXL as a biomarker and therapeutic target in cancer therapy. Pre-clinical and clinical data for anti-AXL therapies to date are also summarized.

AB - AXL is a member of the TAM family, a receptor tyrosine kinase (RTK) subfamily composed of AXL, TYRO-3, and MER. Its main ligand is the vitamin K-dependent protein named growth arrest-specific gene 6 (Gas6). AXL is abnormally activated in many cancers by protein overexpression, point mutations, and gene fusions. The Gas6-AXL axis contributes to tumor progression, invasion, metastasis, and resistance both to chemotherapeutic and targeted anticancer therapies in a wide variety of cancers. In this review, we describe the biology of AXL, review diverse mechanisms of activation and the established and putative roles of AXL as a biomarker and therapeutic target in cancer therapy. Pre-clinical and clinical data for anti-AXL therapies to date are also summarized.

KW - Acquired TKI resistance

KW - Activated mechanisms

KW - AXL

KW - Epithelial-mesenchymal transition (EMT)

KW - Gas6

KW - Overexpression

KW - Point mutations

KW - Receptor tyrosine kinase (RTK)

KW - TAM family

KW - Targeted inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85038892336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038892336&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-0717-2_114

DO - 10.1007/978-1-4419-0717-2_114

M3 - Chapter

SN - 9781441907165

VL - 2-2

SP - 661

EP - 671

BT - Cancer Therapeutic Targets

PB - Springer New York

ER -